S&P 500   3,349.98 (-0.05%)
DOW   27,540.28 (-0.16%)
QQQ   276.82 (-0.14%)
AAPL   114.12 (-0.73%)
MSFT   209.36 (-0.04%)
FB   260.13 (+1.29%)
GOOGL   1,469.05 (+0.71%)
AMZN   3,172.01 (-0.06%)
TSLA   414.71 (-1.54%)
NVDA   520.70 (-0.13%)
BABA   276.58 (+0.21%)
CGC   14.17 (-0.28%)
MU   50.34 (+1.25%)
GE   6.15 (-0.81%)
AMD   80.06 (+0.73%)
T   28.31 (-0.25%)
F   6.64 (-0.75%)
ACB   4.60 (-3.77%)
GILD   62.70 (-0.24%)
NFLX   490.01 (-0.13%)
DIS   124.96 (-0.82%)
BA   163.29 (-1.68%)
BAC   23.83 (-1.08%)
S&P 500   3,349.98 (-0.05%)
DOW   27,540.28 (-0.16%)
QQQ   276.82 (-0.14%)
AAPL   114.12 (-0.73%)
MSFT   209.36 (-0.04%)
FB   260.13 (+1.29%)
GOOGL   1,469.05 (+0.71%)
AMZN   3,172.01 (-0.06%)
TSLA   414.71 (-1.54%)
NVDA   520.70 (-0.13%)
BABA   276.58 (+0.21%)
CGC   14.17 (-0.28%)
MU   50.34 (+1.25%)
GE   6.15 (-0.81%)
AMD   80.06 (+0.73%)
T   28.31 (-0.25%)
F   6.64 (-0.75%)
ACB   4.60 (-3.77%)
GILD   62.70 (-0.24%)
NFLX   490.01 (-0.13%)
DIS   124.96 (-0.82%)
BA   163.29 (-1.68%)
BAC   23.83 (-1.08%)
S&P 500   3,349.98 (-0.05%)
DOW   27,540.28 (-0.16%)
QQQ   276.82 (-0.14%)
AAPL   114.12 (-0.73%)
MSFT   209.36 (-0.04%)
FB   260.13 (+1.29%)
GOOGL   1,469.05 (+0.71%)
AMZN   3,172.01 (-0.06%)
TSLA   414.71 (-1.54%)
NVDA   520.70 (-0.13%)
BABA   276.58 (+0.21%)
CGC   14.17 (-0.28%)
MU   50.34 (+1.25%)
GE   6.15 (-0.81%)
AMD   80.06 (+0.73%)
T   28.31 (-0.25%)
F   6.64 (-0.75%)
ACB   4.60 (-3.77%)
GILD   62.70 (-0.24%)
NFLX   490.01 (-0.13%)
DIS   124.96 (-0.82%)
BA   163.29 (-1.68%)
BAC   23.83 (-1.08%)
S&P 500   3,349.98 (-0.05%)
DOW   27,540.28 (-0.16%)
QQQ   276.82 (-0.14%)
AAPL   114.12 (-0.73%)
MSFT   209.36 (-0.04%)
FB   260.13 (+1.29%)
GOOGL   1,469.05 (+0.71%)
AMZN   3,172.01 (-0.06%)
TSLA   414.71 (-1.54%)
NVDA   520.70 (-0.13%)
BABA   276.58 (+0.21%)
CGC   14.17 (-0.28%)
MU   50.34 (+1.25%)
GE   6.15 (-0.81%)
AMD   80.06 (+0.73%)
T   28.31 (-0.25%)
F   6.64 (-0.75%)
ACB   4.60 (-3.77%)
GILD   62.70 (-0.24%)
NFLX   490.01 (-0.13%)
DIS   124.96 (-0.82%)
BA   163.29 (-1.68%)
BAC   23.83 (-1.08%)
Log in
OTCMKTS:MDIT

Cytocore Stock Forecast, Price & News

$0.0041
0.00 (0.00 %)
(As of 09/28/2020 12:00 AM ET)
Add
Compare
Today's Range
$0.00
Now: $0.00
$0.00
50-Day Range
$0.00
MA: $0.02
$0.03
52-Week Range
$0.00
Now: $0.00
$0.07
Volume2 shs
Average Volume8,430 shs
Market Capitalization$351,894.80
P/E RatioN/A
Dividend YieldN/A
Beta1.73
MEDITE Cancer Diagnostics, Inc. operates as a medical technology company. It develops, manufactures, and markets molecular biomarkers, medical devices, and consumables for the detection, risk assessment, and diagnosis of cancerous and precancerous conditions and related diseases. The company offers USE 33, an ultrasonic decalcification instrument that automatically runs the process under controlled temperatures; TPC 15 Duo and Trio, a tissue processing instrument; TES 99 and TES Valida cooling units; and M530, A550, M380 microtomes for tissue sectioning. It also provides M630, a freezing microtome; TST44, a robotic multi-staining system; COT 20, a linear staining system; and RCM 9000, ACS 720, and TWISTER robotic coverslippers. In addition, the company develops SoftKit device for the self-collection of a sample that can be evaluated to provide an assessment of the health of the entire female genital tract. It sells its products through direct sales and distributors in the United States, China, Europe, and North Africa. The company serves histology and cytology laboratories associated with hospitals or research institutions, and independent laboratories. MEDITE Cancer Diagnostics, Inc. is headquartered in Orlando, Florida.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.70 out of 5 stars


Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:MDIT
CUSIPN/A
Phone407-996-9630

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$6.81 million

Profitability

Miscellaneous

Employees69
Market Cap$351,894.80
Next Earnings DateN/A
OptionableNot Optionable
$0.0041
0.00 (0.00 %)
(As of 09/28/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive MDIT News and Ratings via Email

Sign-up to receive the latest news and ratings for MDIT and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Cytocore (OTCMKTS:MDIT) Frequently Asked Questions

How has Cytocore's stock been impacted by Coronavirus?

Cytocore's stock was trading at $0.04 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, MDIT stock has decreased by 89.8% and is now trading at $0.0041.
View which stocks have been most impacted by COVID-19
.

Who are some of Cytocore's key competitors?

What other stocks do shareholders of Cytocore own?

Who are Cytocore's key executives?

Cytocore's management team includes the following people:
  • Mr. Jeffrey Rencher, Chief Marketing & Bus. Devel. Officer (Age 52)
  • Ms. Susan Weisman, Consultant (Age 58)
  • Mr. Elmar A. Dave, Chief Exec. Officer

What is Cytocore's stock symbol?

Cytocore trades on the OTCMKTS under the ticker symbol "MDIT."

How do I buy shares of Cytocore?

Shares of MDIT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Cytocore's stock price today?

One share of MDIT stock can currently be purchased for approximately $0.00.

How big of a company is Cytocore?

Cytocore has a market capitalization of $351,894.80 and generates $6.81 million in revenue each year. Cytocore employs 69 workers across the globe.

What is Cytocore's official website?

The official website for Cytocore is www.medite-group.com.

How can I contact Cytocore?

Cytocore's mailing address is 4203 SW 34TH STREET, ORLANDO FL, 32811. The company can be reached via phone at 407-996-9630 or via email at [email protected]

This page was last updated on 9/29/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.